ACE releases latest trance of drug guidances (April 2022)


1 April 2022 - The Agency for Clinical Effectiveness has released another batch of drug guidances.

The latest releases are for:

  • Bevacizumab - cervical cancer
  • Aflibercept, bevacizumab and ramucirumab - colorectal cancer
  • Carbonic anhydrase inhibitors - glaucoma, ocular hypertension
  • PARP inhibitors and bevacizumab - ovarian cancer
  • Bevacizumab (biosimilar) - multiple cancers

Read ACE News

Michael Wonder

Posted by:

Michael Wonder